Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer.
Antineoplastic Agents
/ therapeutic use
Biomarkers, Tumor
/ antagonists & inhibitors
Breast Neoplasms
/ drug therapy
Class I Phosphatidylinositol 3-Kinases
/ antagonists & inhibitors
Clinical Decision-Making
DNA Mutational Analysis
Female
Humans
Mutation
Phosphoinositide-3 Kinase Inhibitors
/ therapeutic use
Precision Medicine
Predictive Value of Tests
Prognosis
Signal Transduction
PIK3CA
advanced breast cancer
alpelisib
biomarker
companion diagnostic
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
19
02
2020
revised:
04
06
2020
accepted:
10
06
2020
pubmed:
23
7
2020
medline:
21
7
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
Breast cancer is the most common cancer in women, and approximately 71% of carcinomas are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-not-amplified (HER2-negative). Pathogenesis of breast cancer is associated with dysregulation of several signaling pathways, including the phosphatidylinositol-3-kinase (PI3K) pathway. PIK3CA, the gene encoding PI3K catalytic subunit p110α, is mutated in 20%-40% of breast cancer patients. Several PI3K inhibitors have been developed and one, alpelisib, was recently approved for use in PIK3CA-mutated, HR+, HER2-negative advanced breast cancer. There are numerous types of assays and methods used in clinical studies to determine PIK3CA status in cancers. Additionally, there are several factors to consider for PIK3CA testing in clinical practice, including choice of assay, source of sample, and test timing. In this review, we discuss the use of PIK3CA as a biomarker to guide treatment decisions in patients with HR+, HER2-negative advanced breast cancer, as well as practical considerations and recommendations for testing.
Identifiants
pubmed: 32697890
doi: 10.1002/cam4.3278
pmc: PMC7520347
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Phosphoinositide-3 Kinase Inhibitors
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
6463-6472Informations de copyright
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Nat Rev Cancer. 2015 Jan;15(1):7-24
pubmed: 25533673
N Engl J Med. 2013 Mar 28;368(13):1199-209
pubmed: 23484797
Tumour Biol. 2018 May;40(5):1010428318776169
pubmed: 29775157
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Nat Genet. 2013 Dec;45(12):1446-51
pubmed: 24185510
Clin Genet. 2019 Jun;95(6):643-660
pubmed: 30671931
Lancet Oncol. 2017 Jul;18(7):904-916
pubmed: 28576675
Endocr Relat Cancer. 2019 Jan;26(1):R15-R30
pubmed: 30389903
J Clin Oncol. 2007 Jan 1;25(1):118-45
pubmed: 17159189
PeerJ. 2018 Jun 19;6:e5092
pubmed: 29942710
Lancet Oncol. 2018 Jan;19(1):87-100
pubmed: 29223745
J Clin Oncol. 2010 Jun 1;28(16):2784-95
pubmed: 20404251
Am J Pathol. 2002 Dec;161(6):1961-71
pubmed: 12466110
Clin Breast Cancer. 2016 Jun;16(3):166-79
pubmed: 27103546
Nat Rev Drug Discov. 2009 Aug;8(8):627-44
pubmed: 19644473
Clin Cancer Res. 2015 May 1;21(9):2065-74
pubmed: 25649019
Clin Cancer Res. 2016 Apr 15;22(8):2009-19
pubmed: 26589432
Cancer Cell. 2018 Sep 10;34(3):427-438.e6
pubmed: 30205045
Arch Pathol Lab Med. 2016 Apr 15;140(11):1250-1258
pubmed: 27081877
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
J Cell Biochem. 2018 Jun;119(6):4287-4292
pubmed: 29345357
Breast Cancer (Dove Med Press). 2015 May 15;7:111-23
pubmed: 26028978
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):809-815
pubmed: 28522448
Arch Pathol Lab Med. 2020 Feb 11;:
pubmed: 32045277
J Clin Oncol. 2018 Apr 1;36(10):981-990
pubmed: 29470143
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
pubmed: 16341064
Cancer Med. 2020 Sep;9(18):6463-6472
pubmed: 32697890
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
J Clin Oncol. 2018 Jul 10;36(20):2105-2122
pubmed: 29846122
Nat Genet. 2013 Dec;45(12):1439-45
pubmed: 24185512
J Clin Oncol. 2018 Jun 1;36(16):1631-1641
pubmed: 29504847
Oncotarget. 2016 May 10;7(19):27208-19
pubmed: 27028851
Am J Clin Pathol. 2011 Apr;135(4):592-8
pubmed: 21411782
Oncotarget. 2017 Apr 18;8(16):26414-26423
pubmed: 28061482
Breast Cancer Res. 2011;13(6):224
pubmed: 22114931
Breast Cancer Res. 2013 Oct 01;15(5):R92
pubmed: 24286369
Nat Genet. 2013 Dec;45(12):1415-6
pubmed: 24270445
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593